Regardless, the data presented here provide compelling support for the development of new therapeutic strategies for the combined targeting of SHP2 and MEK in cancer types that have acquired new sensitivities to oncogenic inhibitors once tumor cells have developed SHP2 growth independence. This evidence concerns the gene MAP2K7 and neoplasm.